Hospices civils de Lyon, Hôpital Edouard Herriot, Service d'Hépato-Gastroentérologie, and Université Claude Bernard Lyon 1, Lyon, France.
Hospices civils de Lyon, Hôpital de la Croix Rousse, Service d'Hépato-Gastroentérologie, Lyon, France.
Liver Transpl. 2024 Apr 1;30(4):395-411. doi: 10.1097/LVT.0000000000000278. Epub 2023 Oct 4.
Autoimmune hepatitis (AIH) may recur after liver transplantation (LT). The aims of this study were to evaluate the incidence and risk factors for recurrent autoimmune hepatitis (rAIH). A multicenter retrospective French nationwide study, including all patients aged ≥16 transplanted for AIH, with at least 1 liver biopsy 1 year after LT, was conducted between 1985 and 2018. Risk factors for rAIH were identified using a multivariate Cox regression model. Three hundred and forty-four patients were included (78.8% women) with a median age at LT of 43.6 years. Seventy-six patients (22.1%) developed recurrence in a median time of 53.6 months (IQR, 14.1-93.2). Actuarial risk for developing rAIH was 41.3% 20 years after LT. In multivariate analysis, the strongest risk factor for rAIH was cytomegalovirus D+/R- mismatch status (HR=2.0; 95% CI: 1.1-3.6; p =0.03), followed by associated autoimmune condition. Twenty-one patients (27.6% of rAIH patients) developed liver graft cirrhosis after rAIH. Independent risk factors for these severe forms of rAIH were young age at LT, IgG levels >20.7 g/L, and LT in the context of (sub)fulminant hepatitis. Immunosuppression, especially long-term maintenance of corticosteroid therapy, was not significantly associated with rAIH. Recurrence of AIH after LT is frequent and may lead to graft loss. Recurrence is more frequent in young patients with active disease at the time of LT, yet systematic corticosteroid therapy does not prevent it.
自身免疫性肝炎(AIH)在肝移植(LT)后可能会复发。本研究旨在评估复发性自身免疫性肝炎(rAIH)的发生率和危险因素。这是一项在 1985 年至 2018 年间进行的、包含所有因 AIH 接受 LT、且 LT 后至少有 1 次肝活检的年龄≥16 岁患者的法国多中心回顾性全国性研究。使用多变量 Cox 回归模型确定 rAIH 的危险因素。共纳入 344 例患者(78.8%为女性),LT 时的中位年龄为 43.6 岁。76 例(22.1%)在中位时间 53.6 个月(IQR,14.1-93.2)后复发。LT 后 20 年,rAIH 的累积发生率为 41.3%。多变量分析显示,rAIH 的最强危险因素是巨细胞病毒 D+/R-不匹配状态(HR=2.0;95%CI:1.1-3.6;p=0.03),其次是合并自身免疫性疾病。21 例(rAIH 患者的 27.6%)在 rAIH 后发展为肝移植肝硬化。这些严重 rAIH 形式的独立危险因素包括 LT 时年龄较小、IgG 水平>20.7 g/L 和 LT 处于(亚)暴发性肝炎的背景下。免疫抑制,尤其是长期维持皮质类固醇治疗,与 rAIH 无显著相关性。LT 后 AIH 复发较为常见,可导致移植物丢失。在 LT 时患有活动性疾病的年轻患者中,rAIH 更频繁,但系统性皮质类固醇治疗并不能预防其发生。